Research programme: cancer vaccine - Biocad
Alternative Names: mRNA oncovaccines - BiocadLatest Information Update: 28 Apr 2024
Price :
$50 *
At a glance
- Originator Biocad
- Class Cancer vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for research development in Cancer in Russia (Parenteral)
- 27 Mar 2020 Cancer vaccine - Biocad is available for licensing as of 23 Mar 2020. https://biocadglobal.com/partnership.html
- 23 Mar 2020 Early research in Cancer in Russia (parenteral) before March 2020